In Vitro Antifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries

REFERENCES

• Wingard J. Zygomycosis: epidemiology and treatment op-tions. Adv Stud Med 2006; 6: S526—S530
   Google Scholar
• Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236–301
   PubMed Web of Science ®Google Scholar
• Hibbett DS, Binder M, Bischoff JF, Blackwell M, Cannon PF, Eriksson OE, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res 2007; 111: 509–547
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sark-isova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653
   PubMed Web of Science ®Google Scholar
• Glockner A, Vehreschild JJ, Comely OA. Zygomycosis — current epidemiological aspects. Mycoses; 50 Suppl 1: 50–55
   Google Scholar
• Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomy-cosis (Mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17: 517–525.
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Zygomycosis: reemergence of an old pa-thogen. Clin Infect Dis 2004; 39: 588–560
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360
   PubMed Web of Science ®Google Scholar
• Slavin MA, Szer J, Grigg AP, Roberts AW, Seymour JF, Sasadeusz J, et al; the Mycoses Interest Group of Australasian Society for Infectious Diseases: Guidelines for use of antifungal agents in the treatment of invasive Candida and mould infections (July 2003) Available from: http://www.racp.edu.au/asid—antifungal/antifungal.pdf. Accessed January 07, 2009.
   Google Scholar
• Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000; 30: 653–657
   PubMed Web of Science ®Google Scholar
• Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008; 61 Suppl 1: i35—i39
   Google Scholar
• van Bunk JA, Hare RS, Solomon HF, Corrado ML, Kon-toyiannis DP. Posaconazole is effective as salvage therapy in zy-gomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61—e65. Erratum in: Clin Infect Dis 2006 Nov 15;43: 1376
   Google Scholar
• Greenberg RN, Mullane K, van Bunk JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zy-gomycosis. Antimicrob Agents Chemother 2006; 50: 126–133
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364–371
   PubMed Web of Science ®Google Scholar
• Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on Mucormycosis: pathophysiology, presentation, and manage-ment. Clin Microbiol Rev 2005; 18: 556–569
   PubMed Web of Science ®Google Scholar
• González GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 2009; 47: 71–76
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spick-erman J, Weidekamm E, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intra-venous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 286–293
   PubMed Web of Science ®Google Scholar
• Mouton JW, Verweij PE, Warn P, Denning D, Heep M, Isham N, et al. In vitro activity of a new triazole BAL4815 against Candida isolates with decreased fluconazole susceptibi-lity. 2nd Trends of Medical Mycology (TIMM), Berlin, Germany 2005 Oct 23-26 . Poster no. P-021. ECMM, Paris, France
   Google Scholar
• Breuker I, Meis JF, Verweij PE, Mouton JW. In vitro acti-vity of the new azole BAL4815 against Candida isolates com-prising resistant C. albicans and less susceptible Candida spp. In: Abstracts of the 45th ICAAC, Washington, DC, 2005 Dec 16-19. Abstract-M-1621. ASM, Washington, DC, USA
   Google Scholar
• Seifert H, Aurbach U, Stefanik D, Comely O. In vitro ac-tivities of isavuconazole and other antifungal agents against Can-dida bloodstream isolates. Antimicrob Agents Chemother 2007; 51: 1818–1821
   PubMed Web of Science ®Google Scholar
• Illnait-Zaragozi M-T, Martinez GF, Curfs-Breuker I, Fer-nandez CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other anti-fungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008; 52: 1580–1582
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006; 57: 135–138
   PubMed Web of Science ®Google Scholar
• Pasqualotto A, Denning D. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008; 61: i19—i30
   Google Scholar
• de la Escalera CM, Aller Al, Lopez-Oviedo E, Romero A, Martos Al, Canton E, et al. Activity of BAL 4815 against fila-mentous fungi. J Antimicrob Chemother 2008; 61: 1083-1086
   Google Scholar
• Guinea J, Pebez T, Recio S, Torres-Narbona M, Souza E. In vitro antifungal activities of isavuconazole (BAL4815), vorico-nazole, and fluconazole against 1,007 isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species. Antimicrob Agents Chemother 2008; 52: 1396–1400
   PubMed Web of Science ®Google Scholar
• Gonzalez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 2009; 47: 71–76
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Lechner V, Lass-Flörl C. The in vitro activity of isavuconazole against Aspergillus species and Zy-gomycetes.according to EUCAST methodology. Antimicrob Agents Chemother 2009; 0: AAC.01530-08v1
   Google Scholar
• Warn P, Sharp A, Denning D. In vitro activity of BAL4815 against Zygomycetes. The International Society for human and Animal Mycology (ISHAM), Paris, France 2006 Jun 25-29. Poster P-0158.
   Google Scholar
• Verweij PE, van der Lee HAL, Rijs AJMM. Isavuconazole is active against zygomycetes in vitro. 2nd Trends of Medical My-cology (TIMM), Berlin, Germany 2005 Oct 23-26. Poster no. P-051. ECMM, Paris, France
   Google Scholar
• Ghannoum M, Isham N. Antifungal activity of BAL4815, a novel azole against dermatophytes and emerging non-der-matophyte fungi including zygomycetes. 45th Interscience Con-ference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington DC, 2005 Dec 16–19. Abstract-M-1623. ASM, Washington, DC, USA
   Google Scholar
• Subcommittee of Antifungal Susceptibility Testing of the European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Dis-eases. 2007. Method for the determination of broth dilution min-imum inhibitory concentrations of antifungal agents for conidiaformingmoulds.http : //www. escmid. org/Files/EU-CAST%20moulds%20discussion%1 20document 071019.pdf
   Google Scholar
• Lass-Florl C, Nagl M, Speth C, Ulmer H, Dierich MP, Würzner R. Studies of in vitro activities of voriconazole and itra-conazole against Aspergillus hyphae using viability staining. An-timicrob Agents Chemother 2001; 45: 124–128
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Lugger H, Dierich MP, Lass-Florl C. Posa-conazole enhances the activity of amphotericin B against As-pergillus hyphae in vitro. Antimicrob Agents Chemother 2007; 51: 791–793
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference Me-thod for Broth Dilution Antifungal Susceptibility Testing of Fila-mentous Fungi; Approved Standard — First Edition. CLSIdocument M38-A. Wayne, PA, USA: 2002
   Google Scholar
• Clinical and Laboratory Standards Institute. Reference Me-thod for Broth Dilution Antifungal Susceptibility Testing of Fila-mentous Fungi; Approved Standard — Second Edition. CLSI document M38-A2. Wayne, PA, USA: 2008
   Google Scholar
• Cuenca-Estrella M, GOmez-Lopez A, Mellado E, Buitrago M, Monz6n A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917–921
   Google Scholar
• Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of Zy-gomycetes to conventional and new antifungal agents. Antimi-crob Agents Chemother 2007; 51: 2587-2590
   Google Scholar
• Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itra-conazole, voriconazole, and amphotericin B against a large co-llection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009–2015
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Mosquera J, Spickermann J, Schmitt-Hoffmann A, Heep M, et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic model of dissemininated Aspergillus flauus. J An-timicrob Chemother 2006; 58: 1198–1207
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive as-pergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2–12
   PubMed Web of Science ®Google Scholar